Canaccord Genuity Group Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $73.00

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price upped by Canaccord Genuity Group from $72.00 to $73.00 in a report released on Friday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. A number of other equities analysts have also weighed in on the stock. Royal Bank of […]

Leave a Reply

Your email address will not be published.

Previous post International Flavors & Fragrances (NYSE:IFF) Given New $81.00 Price Target at Citigroup
Next post Stifel Nicolaus Trims Playtika (NASDAQ:PLTK) Target Price to $11.00